These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 24005157)

  • 1. Expanding rare disease drug trials based on shared molecular etiology.
    Brooks PJ; Tagle DA; Groft S
    Nat Biotechnol; 2014 Jun; 32(6):515-8. PubMed ID: 24911489
    [No Abstract]   [Full Text] [Related]  

  • 2. Rare disease specialists and clinical pharmacologists unite: Increase collection of longitudinal data!
    Santen GWE; Cohen AF
    Br J Clin Pharmacol; 2019 Nov; 85(11):2457-2459. PubMed ID: 31486113
    [No Abstract]   [Full Text] [Related]  

  • 3. Innovative methodologies for rare diseases clinical trials.
    Nabbout R; Hilgers RD
    Orphanet J Rare Dis; 2024 May; 19(1):190. PubMed ID: 38715067
    [No Abstract]   [Full Text] [Related]  

  • 4. PI3king apart a rare disease with targeted therapy.
    Newman H; Teachey DT
    Blood; 2023 Mar; 141(9):963-964. PubMed ID: 36862438
    [No Abstract]   [Full Text] [Related]  

  • 5. Author response to comment on "Power of rare diseases: found in translation".
    Fishman MC
    Sci Transl Med; 2014 Mar; 6(228):228lr1. PubMed ID: 24648339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Brain Circuits.
    Mohanta SK; Yin C; Weber C; Godinho-Silva C; Veiga-Fernandes H; Xu QJ; Chang RB; Habenicht AJR
    Circ Res; 2023 May; 132(11):1546-1565. PubMed ID: 37228235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes-Associated Mutations in Proinsulin Provide a "Molecular Rheostat" of Nascent Foldability.
    Dhayalan B; Weiss MA
    Curr Diab Rep; 2022 Feb; 22(2):85-94. PubMed ID: 35119630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical care and therapeutic trials in PLS.
    Floeter MK; Warden D; Lange D; Wymer J; Paganoni S; Mitsumoto H
    Amyotroph Lateral Scler Frontotemporal Degener; 2020 Nov; 21(sup1):67-73. PubMed ID: 33602017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired angiogenesis and extracellular matrix metabolism in autosomal-dominant hyper-IgE syndrome.
    Dmitrieva NI; Walts AD; Nguyen DP; Grubb A; Zhang X; Wang X; Ping X; Jin H; Yu Z; Yu ZX; Yang D; Schwartzbeck R; Dalgard CL; Kozel BA; Levin MD; Knutsen RH; Liu D; Milner JD; López DB; O'Connell MP; Lee CR; Myles IA; Hsu AP; Freeman AF; Holland SM; Chen G; Boehm M
    J Clin Invest; 2020 Aug; 130(8):4167-4181. PubMed ID: 32369445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.
    Roufosse F
    Front Med (Lausanne); 2018; 5():49. PubMed ID: 29682504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Opportunities for Target Discovery in Rare Cancers.
    Sharifnia T; Hong AL; Painter CA; Boehm JS
    Cell Chem Biol; 2017 Sep; 24(9):1075-1091. PubMed ID: 28938087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opportunities and challenges in phenotypic drug discovery: an industry perspective.
    Moffat JG; Vincent F; Lee JA; Eder J; Prunotto M
    Nat Rev Drug Discov; 2017 Aug; 16(8):531-543. PubMed ID: 28685762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitigating risk in academic preclinical drug discovery.
    Dahlin JL; Inglese J; Walters MA
    Nat Rev Drug Discov; 2015 Apr; 14(4):279-94. PubMed ID: 25829283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into the possible role of IFNG and IFNGR1 in Kala-azar and Post Kala-azar Dermal Leishmaniasis in Sudanese patients.
    Salih MA; Fakiola M; Abdelraheem MH; Younis BM; Musa AM; ElHassan AM; Blackwell JM; Ibrahim ME; Mohamed HS
    BMC Infect Dis; 2014 Dec; 14():662. PubMed ID: 25466928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift.
    Medvetz D; Priolo C; Henske EP
    Mol Cancer Res; 2015 Jan; 13(1):3-8. PubMed ID: 25298408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing innovative therapies for neuropathic pain: pros and cons of target-based drug discovery.
    Inglese J
    J Peripher Nerv Syst; 2014 Oct; 19 Suppl 2(Suppl 2):S6-9. PubMed ID: 25269741
    [No Abstract]   [Full Text] [Related]  

  • 17. Integrative analysis of independent transcriptome data for rare diseases.
    Zhang Z; Hailat Z; Falk MJ; Chen XW
    Methods; 2014 Oct; 69(3):315-25. PubMed ID: 24981076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Power of rare diseases: found in translation.
    Fishman MC
    Sci Transl Med; 2013 Sep; 5(201):201ps11. PubMed ID: 24005157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comment on "Power of rare diseases: found in translation".
    van der Meer JW; Simon A; Dinarello CA
    Sci Transl Med; 2014 Jan; 6(219):219le1. PubMed ID: 24431110
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.